JohnnyirishXM

Gilead(GILD) Thread for 2015

644 posts in this topic

welcome to 2015 everyone and lets see how Gild reacts now leading up to 4Q cc end of month..

0

Share this post


Link to post
Share on other sites

@CNBCnow: CVS to give preferred formulary status to Gilead's Harvoni and Sovaldi drugs as of January 7th, DJ reports; shares of $GILD spiking. I saw this on twitter

0

Share this post


Link to post
Share on other sites

Gilead Sciences has added a news release to its Investor Relations website.

Title: Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals' Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases

Date(s): 6-Jan-2015 8:30 AM


 

FOSTER CITY, Calif. & LUDWIGSHAFEN, Germany & HEIDELBERG, Germany--(BUSINESS WIRE)--Jan. 6, 2015-- Gilead Sciences, Inc. (Nasdaq:GILD) and Phenex Pharmaceuticals AG, a privately-held biotechnology company, today announced the signing of a definitive agreement under which Gilead will acquire Phenex's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Under the terms of the agreement, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.

NASH is a common, serious chronic liver disease characterized by inflammation and excessive fat accumulation in the liver and may lead to progressive fibrosis, cirrhosis and liver failure. NASH is estimated to affect 10 to 20 percent of people in the developed world. There are currently no approved therapies to treat NASH. FXR is a nuclear hormone receptor that regulates bile acid, lipid and glucose homeostasis, which can help reduce liver steatosis and inflammation, and may help prevent liver fibrosis.

"This agreement represents a significant milestone for our company and for the field of liver disease research," said Dr. Claus Kremoser, CEO of Phenex Pharmaceuticals AG. "After 15 years of research, FXR is now one of the few clinically validated targets for NASH and we are delighted that Gilead will be continuing the research necessary to more fully realize its potential for advanced liver disease."

"The acquisition of Phenex's FXR program represents an important opportunity to accelerate Gilead's efforts to develop new treatment options that address fibrotic liver diseases," said Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. "We look forward to working closely with Phenex's research and development team to advance the FXR program into clinical development as quickly as possible to explore its potential in areas of significant unmet need."

About Phenex Pharmaceuticals AG

Phenex is a small private German biotechnology company founded in 2002 and located in Ludwigshafen, Germany, with a research site in Heidelberg. Phenex has a long history in nuclear receptor drug discovery and has emerged as a highly specialized leader in the field of difficult to target emerging nuclear receptor targets.

About Gilead Sciences, Inc.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

0

Share this post


Link to post
Share on other sites

Gap fill time?

 

$98.07 - $108.25 ($10.18) :-P

 

After the last few days, I now see a potential run to 105-106 by next week....

0

Share this post


Link to post
Share on other sites

Tony,

 

I plan to sell around $120 whether it is before or after the earnings.

My buy is at $100 of 1000 shares.

 

Then re-buy again if it retraces lower.

0

Share this post


Link to post
Share on other sites

It's obvious that Gilead is no longer the darling in the Biotech sector.

....and insider selling doesn't help!!!

The stock is so undervalued....and we're stuck in the mud.

 

P.S. Celgene hits all-time high

0

Share this post


Link to post
Share on other sites

It's obvious that Gilead is no longer the darling in the Biotech sector.

....and insider selling doesn't help!!!

The stock is so undervalued....and we're stuck in the mud.

 

P.S. Celgene hits all-time high

Jane,YOU IGNORANT SLUT LOL...Gild is still the darling of inst.all that matters,this is last chance to buy under 100 forever,absent split of course..lol..typical,usual low before cc run,about 10 days before cc..expect announcement soon on date..

All deals at discount price done and like i said,Hepc is mostly a medicaid poor persons decease.so who cares about cvs,xscript etc..Ouir Gov't is paying full price and self insured cop and firemen unions also...anyone who works with public in corrections and medical field also get it..Harvoni and sovaldi has already been paid for and gotten by most rich people who have hep=c in 2014..

0

Share this post


Link to post
Share on other sites

WooHoo.... I garnered capital letters. :-P

I did say we were undervalued...THAT'S OBVIOUS TOO!!!

I think institutional ownership will drop again in the Q4. I hope I'm wrong. (Q3 was 86.6%)

 

P.S. You give away your age with those infamous words (in caps). The truly classic days of Saturday Night Live.

0

Share this post


Link to post
Share on other sites

WooHoo.... I garnered capital letters. :-P

I did say we were undervalued...THAT'S OBVIOUS TOO!!!

I think institutional ownership will drop again in the Q4. I hope I'm wrong. (Q3 was 86.6%)

 

P.S. You give away your age with those infamous words (in caps). The truly classic days of Saturday Night Live.

Yes,i knew you were old enough to get it..LOL..i expdect inst in 4Q to be same or higher,most sold and rebought for profit last year..imo..could have rebought in jan tho,so will notreflect it yet..

0

Share this post


Link to post
Share on other sites